BICO News Feed
- March 17, 2025
- 9:53 am
Introducing the CYTENA Therapeutic Monoclonal Antibody Approval Tracker
Introducing the CYTENA Therapeutic Monoclonal Antibody Approval Tracker
Given the incredible growth that has been, and continues to be, exhibited by the global monoclonal antibody (mAb) market, it is becoming increasingly difficult to keep up to date with all the latest mAb therapies. To make this task straightforward, we created a tool to track the current pipeline of mAb therapies that are in the latter clinical phases as well as those that already received market approval.
What’s in the Tracker?
- Drug: The name of the mAb (not the market name).
- Sponsor: The company, or companies, that sponsored the development and clinical research of the mAb. Only active sponsors of the mAb are shown.
- Indication: Lists all indications for which the mAb is currently being investigated as a therapy. In the case of approved mAb therapies, this will only include the indications for which the therapy has received a license.
- Clinical Phase: Indicates whether the mAb therapy is in phase III clinical trials or has received market approval. In cases of an mAb therapy having only been approved in a single country or continent, this information is provided.
- Antibody Type: Indicates the type of mAb, e.g., human, chimeric.
- Drug Target: Refers to the protein or antigen that is being targeted by the mAb. In the case of bispecific mAbs, both targets are listed.
Why Use the Tracker?
The meteoric rise in mAb research has seen the market rapidly evolve, with an ever-increasing number of mAb therapies reaching the latter stages of clinical trials and achieving market approval. Staying up to date with all the emerging mAb therapies is becoming more and more difficult, but it’s crucial that you are aware of the latest developments so that you can establish and solidify your position within the market.
This tracker provides an exhaustive list of promising and approved mAb therapies all in one place. By referring to this list, you can spot the latest trends, identify competitors, and discover potential gaps within the market, making it an essential strategic tool for any company that is developing an mAb therapy.
How to Use the Tracker
Simply scrolling through the tracker is a great way to get an overview of the mAb therapy market and see the different types of therapies that are being developed. Should you want to gain more specific insights, such as the mAb therapies developed for a specific target, just sort by the relevant column and find all the information below.
How Do We Populate the Tracker?
We scour diverse authoritative sources to ensure this tracker is as comprehensive as possible, including:
- Clinical trial databases
- Company websites
- Competitive intelligence
- Research papers
- Press releases
- Company social media
- Market reports
Where possible, we verify the information using multiple sources, with clinical trial databases and company websites taking precedence.
How Often is it Updated?
We update the tracker once to twice yearly to make sure you never miss a beat.
Did we miss something? Let us know what you’d like to see added to the tracker.
How CYTENA Instruments Accelerate Monoclonal Antibody Development
At CYTENA, we support companies developing the next generation of mAbs. Our UP.SIGHT is a dual single-cell dispenser and imager that streamlines cell line development and derisks workflows by providing >99.99% probability of monoclonality. This instrument combines microfluidics and advanced dual-imaging to ensure the gentle and precise isolation of high-yield, genetically stable clones for mAb production, with minimal hands-on time.
If you want to join the automation revolution that so many top companies already benefit from, then the C.STATION from CYTENA is your ultimate solution. The C.STATION provides end-to-end automation for cell line and mAb development that integrates confluency screening, antibody titer measurements, and much more. This enables you to select the highest-performing clones early in the process, saving both time and resources in identifying the best clones.
Ready to see your mAb on the CYTENA therapeutic monoclonal antibody approval tracker with the rest? Visit our product page to discover how our comprehensive suite of instruments can help streamline your mAb development workflow.
Disclaimer: While we endeavor to include all mAb therapies that are currently approved or in phase III clinical trials, some may have been omitted by mistake.
More news
Stay updated
Get the latest first.
